New Rapid UTI Test Research Raises A Key Question For Pharmacies

A rapid urine test developed by researchers at the University of Reading in March 2026 could help clinicians identify suitable antibiotics for urinary tract infections within hours. The NIHR-funded study tested 352 urine samples from patients with suspected UTIs and found 96.95% agreement with the reference method for seven first-line antibiotics. For pharmacies, the findings sharpen a distinction that customers may not see: detecting urinary markers at home using a home testing UTI kit is not the same as identifying which antibiotic is likely to work.

Antibiotic choice depends on organism response

The Reading study is about antibiotic susceptibility. In clinical terms, this means testing whether the bacteria in a urine sample are likely to respond to specific antibiotics. This sits further along the pathway than a customer-facing home test purchased at a pharmacy. However, antibiotic resistance means that the wrong drug may fail even where infection is real. In these cases, a faster susceptibility result – facilitated by a high-quality self-testing kit – could shorten the wait between suspected infection and targeted treatment.

Home UTI tests sit earlier in the decision pathway

A home UTI test can give customers an early indication by detecting markers commonly associated with a urinary infection. Our Suresign UTI test strips, for example, work by detecting leukocytes and nitrites in urine. These markers can raise suspicion of a UTI, but they do not identify the organism causing symptoms. They also do not show whether an antibiotic is needed, which antibiotic should be used, or whether the infection may involve the kidneys. A home self-testing kit result should therefore be treated as one piece of information in a wider medical conversation, not as a treatment decision.

Does this weaken the role of home testing?

No, but it does define it more accurately. The most helpful message to give to customers is that a UTI test result should be interpreted alongside individual symptoms, risk factors and duration – which can vary widely from patient to patient. Therapeutically, the important distinction is between ‘lower’ urinary symptoms that may sit within a pharmacy treatment pathway and features that change the customer’s risk profile. Dysuria, frequency and urgency may support an uncomplicated lower UTI treatment plan, whereas the presence of fever, flank pain, recurrent infections, immune suppression or systemic illness should move the conversation away from over-the-counter treatment and towards follow up with the customer’s GP or urgent clinical assessment.

Next steps

Suresign UTI testing can help pharmacy customers identify the urinary markers associated with infection, while pharmacy teams explain when that result is enough to start a pharmacy discussion and when symptoms need GP or urgent clinical advice. If you’d like to find out more about our home testing UTI kit, please contact one of our technical sales team today by clicking here.